LAUSR

ered as an ordinal variable (better, stable, worse) due to the lack of standardized response assessment. Results: For the 33 patients included in the analysis, median age was 55 years, and 21(64%) males. Seventeen patients (51%) underwent ASCT as first or later line therapy, 13 (39%) received PCDT (excluding steroids) as first or later line therapy. and 10 patients received other therapies. Two patients underwent ASCT twice for total of 19 ASCTs. Eight (42%) ASCT were performed as 1st line treatment and 11 (58%) as later line treatments. Four patients received melphalan 200 mg/ m2, 3 at 140 mg/m2 and for the remaining patients the dose of melphalan was unknown. No patients died within 100 days from ASCT. Across all lines of therapy, 14 patients (82%) had clinical improvement after ASCT compared to 54% of patients treated with PCDT and 27% treated with other immunomodulatory drugs. Overall, 63 % of patients receiving an ASCT achieved a complete hematologic response/ very good partial response (CR/VGPR) compared to 23 % with PCDT or other therapies. Overall, clinical response rates for patients ever achieving CR/VGPR or better was 93% versus 37% for those achieving